Zepbound
Q2 2026 revenue $4.93B; FY2025 revenue up 175%.
The numbers
What it is
Tirzepatide injection for chronic weight management in adults with obesity. Nearly all of its 2025 revenue came from the US.
Why it matters to the stock. Zepbound is the main obesity product in Lilly's US revenue and the core of the obesity franchise that drives the 2026 guidance raise.
News
EloraTZP Phase 2b: eloralintide plus tirzepatide beats tirzepatide 15 mg
Lilly reported Phase 2b results for EloraTZP, a combination of its amylin agonist eloralintide and tirzepatide, on September 30, 2026.
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Medicare GLP-1 Bridge starts July 1 with $50 monthly copay for Zepbound and Foundayo
Eligible Medicare Part D patients can get Zepbound and Foundayo for weight management for $50 a month under the Medicare GLP-1 Bridge program, which started July 1, 2026.
Michigan Supreme Court reverses appeals ruling in Lilly insulin pricing case
Lilly's quarterly report says the Michigan Supreme Court in July 2026 reversed a Michigan Court of Appeals decision in the insulin pricing litigation.
Lilly's Q1 2026 revenue rose 56%; full-year guidance raised
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56%, mainly from volume growth partly offset by lower realized prices.
Lilly's Q4 2025 revenue rose 43%; 2026 guidance set at $80B-$83B
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, driven by volume growth for Mounjaro and Zepbound.